AB Science has a unique and diversified indication portfolio that includes multiple late-stage programs.

Compound

Indication

Therapeutic area

Preclinical

Phase 1/2

Phase 2b/3

Confirmatory Phase 3

NDA/MAA

*: Positive Phase 2B/3 Results Reported